Aurobindo Pharma Posts ₹8,286 Crore Q2 Revenue, ₹848 Crore Net Profit; Steady Growth Amid Challenges

Aurobindo Pharma’s Q2 FY26 consolidated financial results reveal a revenue from operations of ₹8,286 crore and a net profit of ₹848 crore, reflecting the company’s ongoing resilience and strategic expansion. Despite headwinds including operational setbacks such as a fire event at the Pen G facility, the firm maintained its growth trajectory with steady revenues and profitability. The pharmaceutical giant’s European markets experienced strong growth, with key segments like ARV formulations and growth markets showing promising upticks, while the API business faced decline.

 

The EBITDA margins for the quarter settled slightly below company targets at around 20.4%, impacted by increased employee expenses and operational disruptions. Adjusted net profit saw a moderate decline compared to the previous year, attributed to these challenges, yet the company affirmed its guidance on margins and growth for the full fiscal year 2026. Strategic initiatives like new product launches, biosimilar approvals, and acquisitions support its growth outlook.

 

Important points include:

Source: Company earnings release, ICICI Direct, Economic Times, CNBC TV18.